Generation and Analysis of Mice Lacking the Chemokine Fractalkine
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Fractalkine (CX(3)CL1) is the first described chemokine that can exist either as a soluble protein or as a membrane-bound molecule. Both forms of fractalkine can mediate adhesion of cells expressing its receptor, CX(3)CR1. This activity, together with its expression on endothelial cells, suggests that fractalkine might mediate adhesion of leukocytes to the endothelium during inflammation. Fractalkine is also highly expressed in neurons, and its receptor, CX(3)CR1, is expressed on glial cells. To determine the biologic role of fractalkine, we used targeted gene disruption to generate fractalkine-deficient mice. These mice did not exhibit overt behavioral abnormalities, and histologic analysis of their brains did not reveal any gross changes compared to wild-type mice. In addition, these mice had normal hematologic profiles except for a decrease in the number of blood leukocytes expressing the cell surface marker F4/80. The cellular composition of their lymph nodes did not differ significantly from that of wild-type mice. Similarly, the responses of fractalkine(-/-) mice to a variety of inflammatory stimuli were indistinguishable from those of wild-type mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 14×
“Previous reports have revealed that CX3CR1 is expressed on leukocytes (13, 18, 19).”
InfluentialA new class of membrane-bound chemokine with a CX3C motif
Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., & Schall, T. J. (1997) · Nature · doi:10.1038/385640a0 · Cited by 2,013 · cited 5×
“In vitro, this soluble form of human fractalkine has potent chemoattractant activity for the same cell types that adhere to monolayers expressing the membrane-bound form (1).”
Influential
Cited by
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531
“Fractalkine (CX3CL1), the exclusive ligand for CX3CR1, is synthesized as a transmembrane glycoprotein, from which a soluble chemokine can be proteolytically release”
BackgroundSelf-citationTacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28549 · Cited by 1,323
Self-citationHundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3775 · Cited by 713
Onai, N., Obata-Onai, A., Schmid, M. A., Ohteki, T., Jarrossay, D., & Manz, M. G. (2007) · Nature Immunology · doi:10.1038/ni1518 · Cited by 696
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma
Chen, Z., Feng, X., Herting, C. J., Garcia, V. A., Nie, K., Pong, W. W., Rasmussen, R., Dwivedi, B., Seby, S., Wolf, S. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2310 · Cited by 675
Sordi, V., Malosio, M. L., Marchesi, F., Mercalli, A., Melzi, R., Giordano, T., Belmonte, N., Ferrari, G., Leone, B. E., Bertuzzi, F., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3507 · Cited by 602
Fractalkine Preferentially Mediates Arrest and Migration of CD16+ Monocytes
Ancuta, P., Rao, R., Moses, A., Mehle, A., Shaw, S. K., Luscinskas, F. W., & Gabuzda, D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022156 · Cited by 570
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival
Landsman, L., Bar-On, L., Zernecke, A., Kim, K.-W., Krauthgamer, R., Shagdarsuren, E., Lira, S. A., Weissman, I. L., Weber, C., & Jung, S. (2009) · Blood · doi:10.1182/blood-2008-07-170787 · Cited by 490
Self-citationDecreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis
Lesnik, P., Haskell, C. A., & Charo, I. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15555 · Cited by 487
“(29) reported normal development and normal responses in several models of induced inflammation, including experimental peritonitis, delayed-type hypersensitivity, enterocolitis, and infection with Listeria monocytogenes.”
Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice
Combadière, C., Potteaux, S., Gao, J.-L., Esposito, B., Casanova, S., Lee, E. J., Debré, P., Tedgui, A., Murphy, P. M., & Mallat, Z. (2003) · Circulation · doi:10.1161/01.cir.0000057548.68243.42 · Cited by 476
Estrogens, Neuroinflammation, and Neurodegeneration
Villa, A., Vegeto, E., Poletti, A., & Maggi, A. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1007 · Cited by 423
“For instance, in CX3CR1deficient mice (93, 94), the state of microglia activation in response to stimuli, such as LPS or 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP), was much higher than that in wt animals.”
BackgroundAuffray, C., Fogg, D. K., Narni-Mancinelli, E., Senechal, B., Trouillet, C., Saederup, N., Leemput, J., Bigot, K., Campisi, L., Abitbol, M., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081385 · Cited by 422
Fractalkine and CX3CR1 regulate hippocampal neurogenesis in adult and aged rats
Bachstetter, A. D., Morganti, J. M., Jernberg, J., Schlunk, A., Mitchell, S. H., Brewster, K. W., Hudson, C. E., Cole, M. J., Harrison, J. K., Bickford, P. C., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.022 · Cited by 364
Mizutani, M., Pino, P. A., Saederup, N., Charo, I. F., Ransohoff, R. M., & Cardona, A. E. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100421 · Cited by 346
Medina-Contreras, O., Geem, D., Laur, O., Williams, I. R., Lira, S. A., Nusrat, A., Parkos, C. A., & Denning, T. L. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59150 · Cited by 325
Self-citationMicroglia, seen from the CX3CR1 angle
Wolf, Y., Yona, S., Kim, K.-W., & Jung, S. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00026 · Cited by 316
Astrocytes in multiple sclerosis: A product of their environment
Nair, A., Frederick, T. J., & Miller, S. D. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8059-5 · Cited by 313
Microglia in Health and Disease
Ransohoff, R. M., & Khoury, J. E. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020560 · Cited by 303
Astrocytes—Friends or foes in multiple sclerosis?
Williams, A., Piaton, G., & Lubetzki, C. (2007) · Glia · doi:10.1002/glia.20546 · Cited by 302
Huang, D., Shi, F., Jung, S., Pien, G. C., Wang, J., Salazar‐Mather, T. P., He, T. T., Weaver, J. T., Ljunggren, H., Biron, C. A., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5465com · Cited by 284
In vivo structure/function and expression analysis of the CX3C chemokine fractalkine
Kim, K.-W., Vallon-Eberhard, A., Zigmond, E., Farache, J., Shezen, E., Shakhar, G., Ludwig, A., Lira, S. A., & Jung, S. (2011) · Blood · doi:10.1182/blood-2011-04-348946 · Cited by 277
Self-citationCX 3 C Chemokine Fractalkine in Pulmonary Arterial Hypertension
Balabanian, K., Foussat, A., Dorfmüller, P., Durand-Gasselin, I., Capel, F., Bouchet-Delbos, L., Portier, A., Marfaing-Koka, A., Krzysiek, R., Rimaniol, A.-C., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2106007 · Cited by 274
Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury
Soriano, S. G., Amaravadi, L. S., Wang, Y. F., Zhou, H., Yu, G. X., Tonra, J. R., Fairchild-Huntress, V., Fang, Q., Dunmore, J. H., Huszar, D., et al. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00033-4 · Cited by 222
“A recent analysis of fractalkine (FKN)-deficient mice revealed no observable phenotype, with the exception of a lower number of monocytes (Cook et al., 2001).”
BackgroundGautier, E. L., Jakubzick, C., & Randolph, G. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.180505 · Cited by 216
CX3CL1 Is Neuroprotective in Permanent Focal Cerebral Ischemia in Rodents
Cipriani, R., Villa, P., Chece, G., Lauro, C., Paladini, A., Micotti, E., Perego, C., De Simoni, M.-G., Fredholm, B. B., Eusebi, F., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3611-11.2011 · Cited by 166
D'Haese, J. G., Demir, I. E., Friess, H., & Ceyhan, G. O. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903540265 · Cited by 116
“The lack of any major immune system defects, behavioral abnormalities or CNS alterations in engineered fractalkine-knockout mice is of major advantage for carrying out a wide range of experiments with these mice [94].”
BackgroundFractalkine protein localization and gene expression in mouse brain
Tarozzo, G., Bortolazzi, S., Crochemore, C., Chen, S. ‐., Lira, A. S., Abrams, J. S., & Beltramo, M. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10645 · Cited by 105
Self-citationZhang, D., Stumpo, D. J., Graves, J. P., DeGraff, L. M., Grissom, S. F., Collins, J. B., Li, L., Zeldin, D. C., & Blackshear, P. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03930.x · Cited by 37
Metadata
- Authors
- Cook, D. N., Chen, S.-C., Sullivan, L. M., Manfra, D. J., Wiekowski, M. T., Prosser, D. M., Vassileva, G., & Lira, S. A.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2001-05-01
- Volume
- 21
- Issue
- 9
- Pages
- 3159-3165
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2132271411
- Cited by
- 155
- References
- 3
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.